Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03267940
Title Open-Label Study of PEGPH20 With CIS and GEM; PEGPH20 With Atezolizumab, CIS and GEM; and Compared With CIS and GEM Alone in HA-high Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Halozyme Therapeutics
Indications

bile duct adenocarcinoma

gallbladder adenocarcinoma

cholangiocarcinoma

Therapies

Cisplatin + Gemcitabine

Atezolizumab + Cisplatin + Gemcitabine + PEGPH20

Cisplatin + Gemcitabine + PEGPH20

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.